MaxCyte, Inc. (NASDAQ: MXCT) is a clinical‐stage cell therapy platform company that develops and commercializes proprietary flow electroporation technology for the delivery of macromolecules into living cells. The company’s instruments and consumables are designed to support research, preclinical development and clinical‐scale manufacturing of cell therapies across a variety of modalities, including engineered T cells, natural killer (NK) cells and induced pluripotent stem cell (iPSC) therapies. MaxCyte’s platform enables nonviral delivery with high efficiency, viability and scalability, making it suitable for academic institutions, biotechnology companies and pharmaceutical partners.
The core of MaxCyte’s offering is its Flow Electroporation system, which comprises benchtop research instruments and Good Manufacturing Practice (GMP)‐compliant processors tailored to different stages of therapeutic development. Researchers use MaxCyte’s instruments to transiently permeabilize cell membranes, facilitating the uptake of DNA, RNA, proteins or CRISPR/Cas9 components without compromising cell health. In addition to instrument sales, the company generates revenue through the sale of proprietary reagents, disposables and licensing agreements with biopharmaceutical collaborators seeking to harness the platform for novel cell therapy programs.
Founded in 1998 and headquartered in Gaithersburg, Maryland, MaxCyte maintains a global footprint with offices and service centers across North America, Europe and Asia. In July 2016, the company completed its initial public offering on the Nasdaq Stock Market. Under the leadership of President and Chief Executive Officer Doug Doerfler, MaxCyte continues to expand its customer base and partnerships with leading research institutions and pharmaceutical companies, positioning its technology at the forefront of next‐generation cell and gene therapy development.
AI Generated. May Contain Errors.
